These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Compton C; McBryan D; Bucchioni E; Patalano F Pulm Pharmacol Ther; 2013 Oct; 26(5):562-73. PubMed ID: 23748050 [TBL] [Abstract][Full Text] [Related]
25. Chronic obstructive pulmonary disease: new opportunities for drug development. Barnes PJ Trends Pharmacol Sci; 1998 Oct; 19(10):415-23. PubMed ID: 9803832 [TBL] [Abstract][Full Text] [Related]
26. New treatments for chronic obstructive pulmonary disease. Barnes PJ Ann Ist Super Sanita; 2003; 39(4):573-82. PubMed ID: 15098577 [TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300 [TBL] [Abstract][Full Text] [Related]
28. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629 [TBL] [Abstract][Full Text] [Related]
29. Future treatment strategies for COPD. Friedman M Clin Cornerstone; 2003; 5(1):45-51. PubMed ID: 12739311 [TBL] [Abstract][Full Text] [Related]
30. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Hanania NA Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761 [TBL] [Abstract][Full Text] [Related]